2seventy bio (TSVT) reported a Q4 loss Tuesday of $0.37 per diluted share, narrowing from the loss of $1.11 a year earlier.

Four analysts polled by FactSet expected a loss of $0.20.

Revenue in the three months ended Dec. 31 fell to $2.93 million from $10.7 million a year earlier.

Three analysts surveyed by FactSet projected $13.7 million.